55 filings
Page 3 of 3
8-K
soloe4 c2xu1b7mqs10
9 Nov 21
Inhibrx Reports Third Quarter 2021 Financial Results
4:37pm
8-K
1zh zknnd
28 Oct 21
Departure of Directors or Certain Officers
8:50am
8-K
67778qftuttn8391t42i
12 Oct 21
Regulation FD Disclosure
7:50am
8-K
nvh89fy9gzvgwfc5qymi
3 Sep 21
Entry into a Material Definitive Agreement
4:33pm
8-K
5ozf suydk2j2w
9 Aug 21
Inhibrx Reports Second Quarter 2021 Financial Results
4:12pm
8-K
ck1c8e3
21 Jun 21
Entry into a Material Definitive Agreement
4:05pm
8-K
c97pyu vz85ap8
9 Jun 21
Submission of Matters to a Vote of Security Holders
12:00am
8-K
d571nkxvfaeglmhqn41
13 May 21
Inhibrx Reports First Quarter 2021 Financial Results
4:05pm
8-K
mv9euq
12 Mar 21
Results of Operations and Financial Condition
8:55am
8-K
9arf66g4
13 Jan 21
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
9:03am
8-K
e0ji2zh8og4m22 qk53n
5 Jan 21
Inhibrx Announces Phase 1 Dose Escalation Results of
12:00am
8-K
83xnnvid1zaeqzt
13 Nov 20
Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford
4:13pm
8-K
3yiph
12 Nov 20
Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients
6:07am
8-K
p2d7s8x
11 Sep 20
Regulation FD Disclosure
4:24pm
8-K
8tvrp
21 Aug 20
Unregistered Sales of Equity Securities
4:19pm